Comparison between Long- and Short-Acting Erythropoiesis-Stimulating Agents in the Period Required for Haemoglobin Stabilisation in Treatment of Anaemia in Patients with Chronic Kidney Disease
-
- Hayashi Takahiro
- Department of Clinical Pharmacy, School of Medicine, Fujita Health University Faculty of Pharmacy, Meijo University
-
- Nagamatsu Tadashi
- Faculty of Pharmacy, Meijo University
-
- Matsushita Ayako
- Faculty of Pharmacy, Meijo University
-
- Mizuno Tomohiro
- Faculty of Pharmacy, Meijo University Department of Nephrology, School of Medicine, Fujita Health University
-
- Nishibe Seira
- Department of Clinical Pharmacy, School of Medicine, Fujita Health University
-
- Noguchi Ayaka
- Faculty of Pharmacy, Meijo University
-
- Kato Rina
- Faculty of Pharmacy, Meijo University
-
- Toda Takahiro
- Department of Clinical Pharmacy, School of Medicine, Fujita Health University
-
- Tanaka Junko
- Department of Clinical Pharmacy, School of Medicine, Fujita Health University
-
- Takahashi Hiroshi
- Division of Medical Statistics, Fujita Health University
-
- Hayashi Hiroki
- Department of Nephrology, School of Medicine, Fujita Health University
-
- Yuzawa Yukio
- Department of Nephrology, School of Medicine, Fujita Health University
-
- Yamada Shigeki
- Department of Clinical Pharmacy, School of Medicine, Fujita Health University
Bibliographic Information
- Other Title
-
- Comparison between Long- and Short-Acting Erythropoiesis-Stimulating Agents in the Period Required for Haemoglobin Stabilization in Treatment of Anaemia in Patients with Chronic Kidney Disease
Search this article
Abstract
Comparative studies of the potency of long- and short-acting erythropoiesis-stimulating agents (L-ESAs and S-ESAs) on erythropoietic activity in patients with chronic kidney disease without dialysis have not been performed, although L-ESAs are used in many countries. We performed a retrospective analysis of non-dialysis (ND) patients who had received L-ESA or S-ESA. More days were needed for the S-ESA-treated group (368 d) to reach the haemoglobin (Hb) reference range than for the L-ESA-treated group (126 d). Therefore, we investigated risk factors that influence the period until the Hb level reaches the reference range. Patients were classified into two groups by the period until the Hb level was stabilised within the reference range: the short- and long-term group. Two risk factors for delayed Hb stabilisation were identified: age ≥60 years; and administration of an S-ESA for initial treatment. These findings suggest that the Hb level should be carefully monitored during ESA therapy in elderly ND patients, and that the ESA dose should be increased or L-ESA therapy should be utilised to treat renal anaemia.
Journal
-
- Biological and Pharmaceutical Bulletin
-
Biological and Pharmaceutical Bulletin 38 (5), 740-745, 2015
The Pharmaceutical Society of Japan
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001204631411584
-
- NII Article ID
- 130005068083
-
- NII Book ID
- AA10885497
-
- ISSN
- 13475215
- 09186158
-
- NDL BIB ID
- 026355323
-
- PubMed
- 25740003
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed